KCSG BR13-11유방암
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
- 저널 ESMO Open. 2021 Oct; 6(5): 100236.
- 제1저자 김지연, 조은혜
- 교신저자 박연희